Rewiring Access to China's Clinical Fast Track for Advanced Therapies

HOPEWELL, N.J. – September 16, 2026 – In the high-stakes arena of cell and gene therapy (CGT), the science is frequently outpacing the infrastructure required to test it. For global biopharmaceutical companies navigating a constrained financing environment, the traditional, fragmented approach to drug development—where contract manufacturers and clinical research organizations operate in silos—is increasingly viewed as an operational liability. A newly announced strategic alliance between ProBio, a global contract development and manufacturing organization (CDMO), and Kun Tuo, a clinical research organization (CRO) wholly owned by IQVIA, aims to systematically dismantle these silos. By integrating manufacturing with clinical execution, the partnership provides international biotechs with a streamlined, end-to-end bridge into China's highly efficient Investigator-Initiated Trial (IIT) ecosystem.

At its core, the collaboration unites ProBio's established expertise in the chemistry, manufacturing, and controls (CMC) of complex biologics with Kun Tuo's localized clinical trial management. The resulting ecosystem is designed to guide therapeutic candidates seamlessly from early vector engineering and plasmid synthesis straight through to bedside monitoring and clinical data capture in Chinese hospitals. For Western sponsors, this represents far more than a vendor consolidation; it is a strategic maneuver to accelerate human proof-of-concept readouts while drastically optimizing capital efficiency.

Healing the CDMO-CRO Divide in Advanced Therapies

In the development of advanced modalities like autologous CAR-T, in vivo mRNA delivery, and viral vector-mediated gene therapies, the traditional separation between the contract manufacturer and the clinical operations manager creates acute friction. Complex biological therapeutics demand unbroken chains of identity and custody. When a patient's cells are collected at a hospital, shipped for genetic modification, and returned for infusion, any handoff failure between logistics vendors, CDMO release slots, and hospital schedules can result in catastrophic lot expiration.

Furthermore, when clinical research organizations design study protocols without direct alignment with the CDMO's analytical testing laboratories, discrepancies inevitably arise between patient dosing schedules and batch release testing lead times. Handing off CMC documentation from an independent CDMO to a separate regulatory CRO routinely introduces months of redundant document re-authoring and gap analyses.

Quantitative industry benchmarks underscore the business rationale for combining these contract services. Data from the Tufts Center for the Study of Drug Development (CSDD) reveals that programs utilizing an integrated CDMO-CRO model reduce clinical development cycles by 7 to 15 months on average, with certain complex programs saving up to 34 months. This timeline compression yields profound financial returns, increasing Expected Net Present Value (eNPV) by up to $63 million per indication and generating returns on investment that factor in earlier commercial exclusivity and eliminated vendor overlap costs.

"As the demand for innovative therapies continues to grow worldwide, developers increasingly seek partners who can provide seamless support across the drug development lifecycle," said Allen Guo, CEO of ProBio. "By integrating our CDMO capabilities in CGT and biologics with Kun Tuo's world-class clinical operations expertise, we can now offer a seamless pathway from manufacturing to clinical execution, accelerating Investigator-Initiated Trials in China and bringing innovative therapies to patients faster."

ProBio brings significant scale to this equation, having contributed to more than 1,000 GMP batches of cell and gene therapy products and supported over 90 IND approvals and IIT programs globally. Coupled with Kun Tuo's infrastructure of approximately 1,000 clinical research specialists and experience in over 1,400 clinical trials, the alliance effectively eliminates the referral friction that plagues modern drug development.

Navigating China's Evolving Investigator-Initiated Trials

For international biopharma sponsors, the primary draw of this alliance is its ability to unlock China's clinical research ecosystem. Unlike Western clinical sites where patient accrual in rare indications or advanced hematologic cancers can take years, China's top Class 3A medical centers treat thousands of patients monthly in concentrated clinical units. Operating an exploratory trial via the China IIT pathway can be 30% to 50% cheaper on a per-patient basis than conducting equivalent Phase 1 trials under United States or European clinical budgets.

This efficiency has made China the global epicenter for early-stage CGT testing. According to clinical trial registries, IITs have accounted for approximately 90% of all registered cell therapy clinical trials in China, with over 2,500 trials initiated in recent years. However, the regulatory landscape governing these trials has recently undergone a seismic shift.

State Council Order No. 818, which took effect on May 1, 2026, established China's first unified, statutory lifecycle framework for cellular and molecular interventions. Rather than treating IITs as informal academic pilots, Order 818 formalizes the clinical research stage and mandates strict, phase-appropriate GMP compliance for any therapies administered. Investigators and CDMOs can no longer rely on laboratory-grade preparations; therapies must meet rigorous quality attributes, traceability requirements, and batch controls if the data is to be utilized for future IND applications.

This regulatory tightening makes the ProBio-Kun Tuo alliance particularly timely. ProBio's ability to deliver GMP-compliant manufacturing ensures that the therapies meet the elevated CMC requirements of Order 818, while Kun Tuo navigates the complex institutional ethics committee reviews required to activate hospital sites.

"This collaboration allows us to combine Kun Tuo's clinical development expertise in cell and gene therapy with ProBio's robust manufacturing platform, creating a comprehensive solution that addresses the growing demand for integrated IIT services in China," said Linda Wang, General Manager of Kun Tuo. "Together, we will help sponsors navigate the complexities of China's clinical landscape with greater efficiency and confidence."

The Geopolitical and Regulatory Tightrope

While the speed and cost advantages of China's IIT pathway are undeniable, Western sponsors face a complex geopolitical and regulatory tightrope. Cross-border sponsors are subject to strict scrutiny under China's Human Genetic Resources Administration (HGRAC) rules. International biopharma companies cannot independently collect, process, or export Chinese human biospecimens or clinical genetic datasets without an approved domestic partner and regulatory clearance.

Kun Tuo's localized infrastructure provides multinational sponsors with a domestic entity equipped with established standard operating procedures and an audit-ready track record for HGRAC filings. Because Kun Tuo is backed by the global quality management systems of its parent company, IQVIA, it ensures that trial conduct adheres to Good Clinical Practice (ICH-GCP) standards. This is a critical factor for global data portability.

The U.S. Food and Drug Administration (FDA), under 21 CFR 312.120, accepts foreign clinical data not conducted under a U.S. IND provided the studies conform to GCP and can be validated by FDA site inspections. While the FDA generally rejects standalone foreign data from single-country trials as the sole basis for market approval, high-quality China IIT data is routinely accepted as supporting human safety evidence to grant clearance for U.S. INDs and Fast Track designations.

The strategic value of this data cannot be overstated. In an era of tighter life-sciences venture capital, early China IIT data enables biopharma executives to generate human safety and efficacy readouts without burning the cash required to clear full FDA Phase 1 trials.

Recent history provides compelling proof of this model's viability. Belgian startup EsoBiotec partnered with Chinese researchers to execute an IIT in multiple myeloma across hospitals in Wuhan, generating rapid clinical remissions. The quality of this data directly triggered AstraZeneca's $425 million acquisition of EsoBiotec in 2025. Similarly, Legend Biotech's early IIT studies in China for its BCMA CAR-T therapy led to a global licensing collaboration with Johnson & Johnson, resulting in the blockbuster drug Carvykti.

By combining complementary capabilities, ProBio and Kun Tuo are not merely offering a bundled service; they are architecting a de-risked pathway for clinical innovation. For global biopharmaceutical companies seeking to validate next-generation therapeutics, this connected ecosystem offers a vital mechanism to turn promising science into actionable clinical data, ensuring that the therapies of tomorrow do not stall in the operational bottlenecks of today.